Over-the-Counter Marketing of Antiasthma Drug Products; Background Document for Advisory Committee Meeting; Availability; Establishment of a Public Docket and Request for Comments

Riepilogo

The Food and Drug Administration is announcing the availability of a background document for the joint meeting of the Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee, on the over-the-counter (OTC) marketing of antiasthma drug products. Elsewhere in this issue of the Federal Register, the agency is announcing the joint meeting. This action is being taken to ensure that all interested parties are aware of the issues that are the subject of the joint committee discussion. FDA is also announcing that it is establishing a public docket for comments, views, and other information submitted to the agency on these subjects from interested persons.